Ten63 Therapeutics: Funding, Investors & Team (Sep 2026)
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Ten63 Therapeutics has raised $15.9M across 2 funding rounds on record, the most recent an undisclosed round announced in Feb 2026.
Ten63 Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Ten63 Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Ten63 Therapeutics raised $15.9M in a Series A announced in May 2023.
2.8 years later, an undisclosed round was announced in Feb 2026 with no disclosed amount.
Ten63 Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Ten63 Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Ten63 Therapeutics in Biotechnology and Durham
Companies Similar to Ten63 Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Ten63 Therapeutics Funding FAQs
What does Ten63 Therapeutics do?
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
How much funding has Ten63 Therapeutics raised?
Ten63 Therapeutics has raised $15.9M across 2 rounds on record.
When did Ten63 Therapeutics last raise funding?
Ten63 Therapeutics' most recent funding round on record was announced in Feb 2026. The amount was not disclosed.
Who is the CEO of Ten63 Therapeutics?
Marcel Frenkel is listed as CEO at Ten63 Therapeutics.
Where is Ten63 Therapeutics headquartered?
Ten63 Therapeutics is based in Durham, North Carolina, United States.
How many employees does Ten63 Therapeutics have?
Ten63 Therapeutics is in the 11-50 employee band.
About FundedIQ's Ten63 Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ten63 Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.